The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2621-2622 June 15, 2006 Number 24
NextNext

Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Lymphangioleiomyomatosis, a rare lung disease typically affecting women of reproductive age, is characterized by an abnormal proliferation of smooth-muscle cells and the progressive loss of pulmonary function due to destruction of lung parenchyma.1 Long-term survival is rare; in patients with lymphangioleiomyomatosis, respiratory failure often develops within 10 years after diagnosis. Currently, there is no standard-of-care therapy for this disease, although limited success has been reported with hormone therapy or lung transplantation.

The destruction of lung parenchyma has been attributed to an environment conducive to proteolysis resulting from increased expression and activity of matrix metalloproteinases (MMPs). MMP-2, in . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.